655 results on '"Lumry, William"'
Search Results
2. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus
3. Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study
4. A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema
5. Patient outcomes associated with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysis
6. The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
7. Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial
8. Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study
9. Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema
10. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
11. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial
12. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
13. 47 Pharmacokinetics, efficacy, and safety of weekly/biweekly dosing of Xembify® in treatment-experienced patients, and loading/maintenance dosing in treatment-naïve patients with primary immunodeficiency
14. Correction: Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age
15. Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age
16. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial
17. Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management
18. Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: Results of the Double-blind, Placebo-controlled Phase 3 KONFIDENT Trial
19. Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema
20. Understanding The Reasons Not To Treat All HAE Attacks And Patient Satisfaction For On-Demand Treatment (ODT). Results From The HAE Wave II Disease Specific Program™ (DSP™) 2023
21. Treatment Patterns of Patients Requiring Redosing of an On-demand Treatment After the Return of an HAE Attack
22. Real-World Treatment Outcomes in Patients With Hereditary Angioedema Receiving Lanadelumab or Other Long-Term Prophylaxis
23. Berotralstat Prophylaxis Reduces HAE Attack Rates Regardless of Baseline Attacks: Real-World Outcomes
24. Characterizing the HAE Patient Perspective on First-Line Prophylactic Treatment
25. Triggers of Exacerbation in Chronic Urticaria and Recurrent Angioedema—Prevalence and Relevance
26. Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)
27. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema
28. Association Between Self-Reported Dental Hygiene Practices and Dental Procedure-Related Recurrent Angioedema Attacks in HAE Subjects: A Multicenter Survey
29. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
30. International Consensus on the Use of Genetics in the Management of Hereditary Angioedema
31. Garadacimab for the prevention of hereditary angioedema attacks: a plain language summary of the VANGUARD study
32. A phase 2 open‐label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema
33. Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy
34. Current state of hereditary angioedema management: A patient survey
35. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks
36. Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study
37. A Consensus Parameter for the Evaluation and Management of Angioedema in the Emergency Department
38. A phase 2 open‐label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema.
39. An expert panel's review on patients with hereditary angioedema switching from attenuated androgens to oral prophylactic therapy.
40. Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat
41. Lanadelumab in patients 2 to <12 years old with hereditary angioedema: results from the Phase 3 SPRING Study
42. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema
43. The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update
44. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
45. Pharmacoeconomics of Orphan Disease Treatment with a Focus on Hereditary Angioedema
46. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility
47. Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy
48. Treatment with Sebetralstat Reduces the Cumulative Symptom Severity of Hereditary Angioedema Attacks in a Phase 2 Trial
49. Comparison of Selected Health and Well Being Characteristics in Seniors with Hereditary Angioedema (HAE) and a Non-HAE Patient Matched Cohort
50. Berotralstat Improved Quality of Life through 96 Weeks Across Multiple Subgroups of Patients with Hereditary Angioedema
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.